This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hoffmann, T. K. Articles by Whiteside, T. L. Search for Related Content PubMed PubMed Citation Articles by Hoffmann, T. K. Articles by Whiteside, T. L.

Frequencies of Tetramer⁺ T Cells Specific for the Wild-Type Sequence p53_264–272 Peptide in the Circulation of Patients with Head and Neck Cancer¹

University of Pittsburgh Cancer Institute [T. K. H., A. D. D., V. S. D., A. B. D., T. L. W.], Department of Medicine [A. D. D., V. S. D.], Department of Immunology and Infectious Disease, Graduate School of Public Health [A. D. D.], Magee Research Institute [U. F-H.], Department of Pathology [S. D. F., A. B. D., T. L. W.], and Department of Otolaryngology [E. N. M., T. L. W.], University of Pittsburgh, Pittsburgh, Pennsylvania 15213, and National Cancer Institute, Bethesda, Maryland 20892 [E. A.]

Immunization with wild-type sequence (wt) p53 epitopes represents a novel therapeutic strategyfor cancer patients with tumors accumulating mutant p53. To evaluate usefulness of p53-derived peptides as future cancer vaccines, frequencies of wt p53_264–272 peptide-specific CD8⁺ T cells were determined in the peripheral circulation of patients with squamous cell carcinoma of the head and neck (SCCHN). T cells of 30 HLA-A2.1⁺ patients and 31 HLA-A2.1⁺ healthy individuals were evaluated by multicolor flow cytometry analysis using peptide-HLA-A2.1 complexes (tetramers). T cells specific for an influenza matrix peptide (a model recall antigen) or an HIV reverse transcriptase peptide (a model novel antigen) were studied in parallel. Patients with SCCHN had a significantly higher mean frequency of CD8⁺ T cells specific for wt p53_264–272 than normal donors (P = 0.0041). Surprisingly, the frequency of epitope-specific T cells in the circulation of patients did not correlate with p53 accumulation in the tumor. In patients whose tumors had normal p53 expression or had p53 gene mutations preventing presentation of this epitope, high frequencies of wt p53_264–272-specific CD8⁺ T cells were found, of which many were memory T cells. In contrast, patients whose tumors accumulated p53 had low frequencies of wt p53_264–272-specific CD8⁺ T cells, which predominantly had a naive phenotype and were unable to proliferate ex vivo in response to the epitope, as reported by us previously (T. K. Hoffmann, J. Immunol., 165: 5938–5944, 2000). This seemingly contradictory relationship between the high frequency of epitope-specific T cells and wt p53 expression in the tumor suggests that other factors may contribute to the observed anti-p53 responses. Human papillomavirus-16 E6/E7 expression is common in SCCHN, and E6 is known to promote presentation of wt p53 epitopes. Although human papillomavirus-16 E6/E7 expression was detected in 46% of the tumors, it did not correlate with the frequency of wt p53_264–272-specific CD8⁺ T cells or with p53 expression in the tumor. These findings emphasize the complexity of interactions between the tumor and the host immune system, and, thus, have particularly important implications for future p53-based immunization strategies.

This article has been cited by other articles:

				N. J. Nesslinger, R. A. Sahota, B. Stone, K. Johnson, N. Chima, C. King, D. Rasmussen, D. Bishop, P. S. Rennie, M. Gleave, et al. Standard Treatments Induce Antigen-Specific Immune Responses in Prostate Cancer Clin. Cancer Res., March 1, 2007; 13(5): 1493 - 1502. [Abstract] [Full Text] [PDF]

				A. Jewett, C. Head, and N.A. Cacalano Emerging Mechanisms of Immunosuppression in Oral Cancers. J. Dent. Res., December 1, 2006; 85(12): 1061 - 1073. [Abstract] [Full Text] [PDF]

				D. Ito, A. Albers, Y. X. Zhao, C. Visus, E. Appella, T. L. Whiteside, and A. B. DeLeo The Wild-Type Sequence (wt) p5325-35 Peptide Induces HLA-DR7 and HLA-DR11-Restricted CD4+ Th Cells Capable of Enhancing the Ex Vivo Expansion and Function of Anti-wt p53264-272 Peptide CD8+ T Cells J. Immunol., November 15, 2006; 177(10): 6795 - 6803. [Abstract] [Full Text] [PDF]

				A. Albers, K. Abe, J. Hunt, J. Wang, A. Lopez-Albaitero, C. Schaefer, W. Gooding, T. L. Whiteside, S. Ferrone, A. DeLeo, et al. Antitumor Activity of Human Papillomavirus Type 16 E7-Specific T Cells against Virally Infected Squamous Cell Carcinoma of the Head and Neck Cancer Res., December 1, 2005; 65(23): 11146 - 11155. [Abstract] [Full Text] [PDF]

				C. J. Cohen, Z. Zheng, R. Bray, Y. Zhao, L. A. Sherman, S. A. Rosenberg, and R. A. Morgan Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR J. Immunol., November 1, 2005; 175(9): 5799 - 5808. [Abstract] [Full Text] [PDF]

				A. Mueller, B. W. Schafer, S. Ferrari, M. Weibel, M. Makek, M. Hochli, and C. W. Heizmann The Calcium-binding Protein S100A2 Interacts with p53 and Modulates Its Transcriptional Activity J. Biol. Chem., August 12, 2005; 280(32): 29186 - 29193. [Abstract] [Full Text] [PDF]

				N. Sirianni, P. K. Ha, M. Oelke, J. Califano, W. Gooding, W. Westra, T. L. Whiteside, W. M. Koch, J. P. Schneck, A. DeLeo, et al. Effect of Human Papillomavirus-16 Infection on CD8+ T-Cell Recognition of a Wild-Type Sequence p53264-272 Peptide in Patients with Squamous Cell Carcinoma of the Head and Neck Clin. Cancer Res., October 15, 2004; 10(20): 6929 - 6937. [Abstract] [Full Text] [PDF]

				D. Nagorsen, C. Scheibenbogen, F. M. Marincola, A. Letsch, and U. Keilholz Natural T Cell Immunity against Cancer Clin. Cancer Res., October 1, 2003; 9(12): 4296 - 4303. [Abstract] [Full Text] [PDF]